Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Liver X receptors regulate adrenal cholesterol balance
Carolyn L. Cummins, … , David J. Mangelsdorf, Jean-Marc A. Lobaccaro
Carolyn L. Cummins, … , David J. Mangelsdorf, Jean-Marc A. Lobaccaro
Published July 3, 2006
Citation Information: J Clin Invest. 2006;116(7):1902-1912. https://doi.org/10.1172/JCI28400.
View: Text | PDF
Research Article Endocrinology

Liver X receptors regulate adrenal cholesterol balance

  • Text
  • PDF
Abstract

Cholesterol is the obligate precursor to adrenal steroids but is cytotoxic at high concentrations. Here, we show the role of the liver X receptors (LXRα and LXRβ) in preventing accumulation of free cholesterol in mouse adrenal glands by controlling expression of genes involved in all aspects of cholesterol utilization, including the steroidogenic acute regulatory protein, StAR, a novel LXR target. Under chronic dietary stress, adrenal glands from Lxrαβ–/– mice accumulated free cholesterol. In contrast, wild-type animals maintained cholesterol homeostasis through basal expression of genes involved in cholesterol efflux and storage (ABC transporter A1 [ABCA1], apoE, SREBP-1c) while preventing steroidogenic gene (StAR) expression. Upon treatment with an LXR agonist that mimics activation by oxysterols, expression of these target genes was increased. Basally, Lxrαβ–/– mice exhibited a marked decrease in ABCA1 and a derepression of StAR expression, causing a net decrease in cholesterol efflux and an increase in steroidogenesis. These changes occurred under conditions that prevented the acute stress response and resulted in a phenotype more specific to the loss of LXRα, including hypercorticosteronemia, cholesterol ester accumulation, and adrenomegaly. These results imply LXRα provides a safety valve to limit free cholesterol levels as a basal protective mechanism in the adrenal gland, where cholesterol is under constant flux.

Authors

Carolyn L. Cummins, David H. Volle, Yuan Zhang, Jeffrey G. McDonald, Benoît Sion, Anne-Marie Lefrançois-Martinez, Françoise Caira, Georges Veyssière, David J. Mangelsdorf, Jean-Marc A. Lobaccaro

×

Figure 5

LXR effects in mouse and human adrenal cells.

Options: View larger image (or click on image) Download as PowerPoint
LXR effects in mouse and human adrenal cells.
(A) Northern blot analysis...
(A) Northern blot analysis of ABCA1 and StAR from mouse Y1 cells treated with vehicle, LXR agonist T1317 (1 μM), or RXR agonist LG268 (1 μM) for 6 hours. Quantitation was performed by densitometry using the largest transcript for StAR normalized to β-actin. (B) Western blot analysis of StAR from Y1 cells treated with or without 1 μM LXR agonist T1317 (20 μg per lane, n = 4) for 24 hours. (C) QPCR analysis from human H295R cells treated with vehicle, T1317 (1 μM), LG268 (1 μM), or both ligands for 24 hours. Data represent the mean ± SD (n = 3). Cycle times for the highest expressing group for each gene are shown in the corresponding bar. *P < 0.05, significantly different from control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts